- cafead Jan 13, 2021 at 11:42: AM
via German biotech CureVac shouldn’t be discounted from being a major COVID-19 vaccine player despite being at the tail end of the race to market.
This is according to Marianne De Backer, Bayer’s head of business development who would have helped pen its vaccine deal with CureVac, speaking at the annual J.P. Morgan healthcare conference today.
article source
This is according to Marianne De Backer, Bayer’s head of business development who would have helped pen its vaccine deal with CureVac, speaking at the annual J.P. Morgan healthcare conference today.
article source